Wells Fargo’s MoonLake Immunotherapeutics MLTX Stock Holding History

Wells Fargo’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$233K	Buy	12,520 +2,520	+25%	+$41.7K	﹤0.01%	4618
2025 Q4	$132K	Buy	10,000 +4,792	+92%	+$56.5K	﹤0.01%	5271
2025 Q3	$37.3K	Buy	5,208 +4,483	+618%	+$234K	﹤0.01%	5641
2025 Q2	$34.2K	Hold	725	–	–	﹤0.01%	5637
2025 Q1	$28.3K	Buy	725 +400	+123%	+$17.2K	﹤0.01%	5589
2024 Q4	$17.6K	Buy	325 +25	+8%	+$1.28K	﹤0.01%	5798
2024 Q3	$15.1K	Buy	300 +200	+200%	+$9.37K	﹤0.01%	5705
2024 Q2	$4.4K	Hold	100	–	–	﹤0.01%	5893
2024 Q1	$5.02K	Hold	100	–	–	﹤0.01%	5890
2023 Q4	$6.04K	Hold	100	–	–	﹤0.01%	5932
2023 Q3	$5.7K	Buy	+100	New	+$5.52K	﹤0.01%	5934

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wells Fargo's MLTX Position: Q1 2026 in Review

Wells Fargo increased its MoonLake Immunotherapeutics (MLTX) stake by 25% in Q1 2026, buying an estimated $41.7K and bringing the position to 12,520 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #4618.

Wells Fargo first reported a position in MLTX in Q3 2023 and has held it in 11 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Wells Fargo held 12,520 shares of MoonLake Immunotherapeutics worth $233K as of Q1 2026.
Wells Fargo bought 2,520 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $41.7K.
MoonLake Immunotherapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4618 holding.
Wells Fargo first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 11 quarters since.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.